Determining toxicity risk in CAR T-cell therapy
US12163952B2 · kind B2 · utility
Assignee
Inventors
- Brian CHRISTIN
- Michael Gerard Covington
- Kedar Himanshu DAVE
- Richard James Getto, Jr.
- Tom KOWSKI
- Ryan P. LARSON
- Christopher Glen RAMSBORG
- Nikolaus Sebastian TREDE
- Clinton WEBER
- James Boyd Whitmore
- Nathan K. Yee
- Pascal BEAUCHESNE
- Travis Beckett
- Samuel Charles Blackman
- Nathaniel CHARTRAND
- Mel Davis-Pickett
- Mark J. GILBERT
- Nathaniel LAMBERT
- He Li
- Mary MALLANEY
- Kathryn Lindsay Pollock
- Valerie Odegard
- Jeff SMITH
- Claire L. SUTHERLAND
- Andrew W. Walker
Key dates
| Filing date | Feb 27, 2018 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Nov 7, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.